Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Linq Research LLC

Neither a doctor nor a teaching hospital

Research payments

$7,546,258

1,428 payments

Through program year 2025, Linq Research LLC is reported as receiving $7,546,258 in research payments, across 1,428 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,484,710 100
2024 Research $2,068,777 181
2023 Research $752,582 425
2022 Research $1,181,572 544
2021 Research $895,155 104
2020 Research $851,509 44
2019 Research $311,952 30

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $2,389,968 223 payments
  2. Moderna TX, Inc. $1,304,820 841 payments
  3. AstraZeneca Pharmaceuticals LP $1,102,370 12 payments
  4. Braintree Laboratories, Inc. $674,203 22 payments
  5. Allergan Inc. $372,357 48 payments
  6. Biogen, Inc. $366,616 2 payments
  7. AbbVie, Inc. $279,002 62 payments
  8. Bausch Health US, LLC $226,804 114 payments
  9. Vanda Pharmaceuticals Inc. $201,122 26 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $169,237 21 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 123 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability Immunogenicity and Efficacy of Sarscov2 Rna Vaccine Candidates Against Covid19 in Healthy Adults $1,261,465 88 payments
  2. A Phase 1/2, Randomized, Observer-Blind, Active-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity and Immunogenicity of mRNA-1468, a Candidate Vaccine to Prevent Herpes Zoster (HZ) in Healthy Adults 50 Years of Age $688,812 303 payments
  3. Phase 1/2, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1020 and mRNA-1030 Candidate Seasonal Influenza Vaccines in Healthy Adults $463,711 452 payments
  4. A Phase 2 Study of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (CYPRESS) (CYPRESS) $366,616 2 payments
  5. A Phase 3 Placebocontrolled Randomized Observerblinded Study to Evaluate the Efficacy Safety and Tolerability of A Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $361,179 48 payments
  6. A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease $347,101 11 payments
  7. A Phase 3 Master Protocol to Evaluate Additional Doses of Bnt162b2 in Healthy Individuals Previously Vaccinated With Bnt162b2 $338,318 33 payments
  8. A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis $306,079 7 payments
  9. a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure $295,818 1 payment
  10. A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria $262,546 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record